1. Home
  2. VIGL vs GNLX Comparison

VIGL vs GNLX Comparison

Compare VIGL & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIGL
  • GNLX
  • Stock Information
  • Founded
  • VIGL 2020
  • GNLX 2001
  • Country
  • VIGL United States
  • GNLX United States
  • Employees
  • VIGL N/A
  • GNLX N/A
  • Industry
  • VIGL Biotechnology: Pharmaceutical Preparations
  • GNLX Biotechnology: Pharmaceutical Preparations
  • Sector
  • VIGL Health Care
  • GNLX Health Care
  • Exchange
  • VIGL Nasdaq
  • GNLX Nasdaq
  • Market Cap
  • VIGL 89.3M
  • GNLX 85.0M
  • IPO Year
  • VIGL 2022
  • GNLX 2023
  • Fundamental
  • Price
  • VIGL $2.76
  • GNLX $5.34
  • Analyst Decision
  • VIGL Strong Buy
  • GNLX Strong Buy
  • Analyst Count
  • VIGL 5
  • GNLX 4
  • Target Price
  • VIGL $21.00
  • GNLX $18.25
  • AVG Volume (30 Days)
  • VIGL 2.7M
  • GNLX 386.7K
  • Earning Date
  • VIGL 03-25-2025
  • GNLX 03-31-2025
  • Dividend Yield
  • VIGL N/A
  • GNLX N/A
  • EPS Growth
  • VIGL N/A
  • GNLX N/A
  • EPS
  • VIGL N/A
  • GNLX N/A
  • Revenue
  • VIGL N/A
  • GNLX $8,000.00
  • Revenue This Year
  • VIGL N/A
  • GNLX N/A
  • Revenue Next Year
  • VIGL N/A
  • GNLX N/A
  • P/E Ratio
  • VIGL N/A
  • GNLX N/A
  • Revenue Growth
  • VIGL N/A
  • GNLX N/A
  • 52 Week Low
  • VIGL $1.49
  • GNLX $1.60
  • 52 Week High
  • VIGL $6.06
  • GNLX $8.67
  • Technical
  • Relative Strength Index (RSI)
  • VIGL 70.15
  • GNLX 72.84
  • Support Level
  • VIGL $2.54
  • GNLX $4.10
  • Resistance Level
  • VIGL $2.88
  • GNLX $5.89
  • Average True Range (ATR)
  • VIGL 0.22
  • GNLX 0.54
  • MACD
  • VIGL 0.03
  • GNLX 0.14
  • Stochastic Oscillator
  • VIGL 85.19
  • GNLX 79.70

About VIGL Vigil Neuroscience Inc.

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.

About GNLX Genelux Corporation

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.

Share on Social Networks: